The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients

The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients Publisher Pubmed

Aslani M¹ ; Ahmadzadeh A² ; Rezaieyazdi Z³ ; Mortazavijahromi SS¹ ; Barati A¹ ; Hosseini M⁴ ; Mirshafiey A^{1, 5}

Show Affiliations

1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Rheumatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4. Department of Drug Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
5. Research Centre for Immunodeficiencies, Children's Medical Centre, Tehran University of Medical Sciences, Tehran, Iran

Source: Recent Patents on Inflammation and Allergy Drug Discovery Published:2020

Abstract

Background: Regarding the leukocytes infiltration into the synovium of Rheumatoid Arthritis (RA) patients is mostly mediated by chemokine ligands and receptors, and following the efficient and motivating results of international Phase III clinical trial of β-D-Mannuronic acid (M2000) patented EP067919 (2017), as a novel anti-inflammatory drug, in patients with RA, the present research was designed. Objectives: This study aimed to assess the oral administration effects of this new drug on gene expression of some chemokine receptors and ligands, including CXCR4, CXCR3, CCR2, CCR5 and CCL2/MCP-1 in PBMCs of patients with active form of RA. Methods: Twelve patients suffering from RA, with inadequate response to conventional drugs were selected (Clinical trial identifier IRCT2017100213739N10) and 1000mg/day of M2000 was orally ad-ministrated to them for 12 weeks. The mRNA expression of target molecules was then evaluated in PBMCs of the patients before and after treatment with M2000 using real-time PCR and was compared to healthy controls. Patents related to this study were also reviewed. Results: The results showed that M2000 was able to significantly down-regulate the mRNA expression of CXCR4, CCR2 and CCL2/MCP-1 in the PBMCs of the RA patients. It should be noted that the gene expression situation of the target molecules was in coordinate with the clinical and paraclinical assessments in the patients. Conclusion: Taken together, the results of this investigation revealed the part of molecular and immunological mechanisms of drug Mannuronic acid (M2000) in the treatment of RA, based on chemokine ligands and receptors mediated processes. © 2020 Bentham Science Publishers.

Related Docs

View other Related Docs

1. Influence of Β-D-Mannuronic Acid, As a New Member of Non-Steroidal An-Ti-Inflammatory Drugs Family, on the Expression Pattern of Chemokines and Their Receptors in Rheumatoid Arthritis, Current Drug Discovery Technologies (2021)

2. International Multicenter Randomized, Placebo-Controlled Phase Iii Clinical Trial of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2019)

3. The Role of Β-D-Mannuronic Acid, As a New Non-Steroidal Anti-Inflammatory Drug on Expression of Mir-146A, Irak1, Traf6, Nf-Κb and Pro-Inflammatory Cytokines Following a Clinical Trial in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)

4. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)

5. Immunopharmacological Effect of Β-D-Mannuronic Acid (M2000), As a New Immunosuppressive Drug, on Gene Expression of Mir-155 and Its Target Molecules (Socs1, Ship1) in a Clinical Trial on Rheumatoid Arthritis Patients, Drug Development Research (2020)

6. Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients, Iranian Journal of Allergy# Asthma and Immunology (2022)

7. The Inhibitory Role of M2000 (Β-D-Mannuronic Acid) on Expression of Toll-Like Receptor 2 and 4 in Ht29 Cell Line, Recent Patents on Inflammation and Allergy Drug Discovery (2019)

8. A Controlled, Randomized Phase Ii Clinical Trial for Efficacy and Safety Evaluation of Mannuronic Acid in Secondary Progressive Form of Multiple Sclerosis, International Journal of Neuroscience (2022)

Experts (# of related papers)

View all Related Experts

Mahdi Mahmoudi (9)

Ahmad Reza Jamshidi (7)

Style	Citing Format
MLA	Aslani M, et al.. "The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients." Recent Patents on Inflammation and Allergy Drug Discovery, vol. 14, no. 1, 2020, pp. 69-77.
APA	Aslani M, Ahmadzadeh A, Rezaieyazdi Z, Mortazavijahromi SS, Barati A, Hosseini M, Mirshafiey A (2020). The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients. Recent Patents on Inflammation and Allergy Drug Discovery, 14(1), 69-77.
Chicago	Aslani M, Ahmadzadeh A, Rezaieyazdi Z, Mortazavijahromi SS, Barati A, Hosseini M, Mirshafiey A. "The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients." Recent Patents on Inflammation and Allergy Drug Discovery 14, no. 1 (2020): 69-77.
Harvard	Aslani M et al. (2020) 'The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients', Recent Patents on Inflammation and Allergy Drug Discovery, 14(1), pp. 69-77.
Vancouver	Aslani M, Ahmadzadeh A, Rezaieyazdi Z, Mortazavijahromi SS, Barati A, Hosseini M, et al.. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients. Recent Patents on Inflammation and Allergy Drug Discovery. 2020;14(1):69-77.
BibTex	@article{ author = {Aslani M and Ahmadzadeh A and Rezaieyazdi Z and Mortazavijahromi SS and Barati A and Hosseini M and Mirshafiey A}, title = {The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients}, journal = {Recent Patents on Inflammation and Allergy Drug Discovery}, volume = {14}, number = {1}, pages = {69-77}, year = {2020} }
RIS	TY - JOUR AU - Aslani M AU - Ahmadzadeh A AU - Rezaieyazdi Z AU - Mortazavijahromi SS AU - Barati A AU - Hosseini M AU - Mirshafiey A TI - The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients JO - Recent Patents on Inflammation and Allergy Drug Discovery VL - 14 IS - 1 SP - 69 EP - 77 PY - 2020 ER -

Style

Citing Format

MLA

Aslani M, et al.. "The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients." Recent Patents on Inflammation and Allergy Drug Discovery, vol. 14, no. 1, 2020, pp. 69-77.

APA

Aslani M, Ahmadzadeh A, Rezaieyazdi Z, Mortazavijahromi SS, Barati A, Hosseini M, Mirshafiey A (2020). The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients. Recent Patents on Inflammation and Allergy Drug Discovery, 14(1), 69-77.

Chicago

Aslani M, Ahmadzadeh A, Rezaieyazdi Z, Mortazavijahromi SS, Barati A, Hosseini M, Mirshafiey A. "The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients." Recent Patents on Inflammation and Allergy Drug Discovery 14, no. 1 (2020): 69-77.

Harvard

Aslani M et al. (2020) 'The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients', Recent Patents on Inflammation and Allergy Drug Discovery, 14(1), pp. 69-77.

Vancouver

Aslani M, Ahmadzadeh A, Rezaieyazdi Z, Mortazavijahromi SS, Barati A, Hosseini M, et al.. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients. Recent Patents on Inflammation and Allergy Drug Discovery. 2020;14(1):69-77.

BibTex

@article{ author = {Aslani M and Ahmadzadeh A and Rezaieyazdi Z and Mortazavijahromi SS and Barati A and Hosseini M and Mirshafiey A}, title = {The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients}, journal = {Recent Patents on Inflammation and Allergy Drug Discovery}, volume = {14}, number = {1}, pages = {69-77}, year = {2020} }

RIS

TY - JOUR
AU - Aslani M
AU - Ahmadzadeh A
AU - Rezaieyazdi Z
AU - Mortazavijahromi SS
AU - Barati A
AU - Hosseini M
AU - Mirshafiey A
TI - The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients
JO - Recent Patents on Inflammation and Allergy Drug Discovery
VL - 14
IS - 1
SP - 69
EP - 77
PY - 2020
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract